Why does tesamorelin gel? A complete guide to gelation after reconstitution

Yes, tesamorelin is really more prone to gelling and more dense than most others of peptides. This is not It's a sure sign that you've definitely got it faulty batch. Ten the guide explains precisely why tesamorelin is prone to gelation, what the manual actually says manufacturer, what actually causes this in in practice, how to reduce the risk, and what what to do and what not to do if It has already happened. Amino acid sequence Tesamorelin comprises a sequence hydrophobic residues that make a molecule more prone to self-association, meaning molecules sticking together, than many other reconstituted peptides. This tendency is sufficiently well known that it appears in peptide handling literature, and even shapes some official pharmaceutical formulation choices for the FDA-approved product [1][2][3].

Gelling can be triggered or worsened by shaking instead of gentle mixing, the use of an inappropriate or poor-quality solvent, temperature fluctuations, high concentration, and storage conditions. Most of these factors can be avoided [1][2][4].

Once tesamorelin has visibly gelled, turned cloudy or solidified, it should not be used. A properly reconstituted, usable solution should be clear and colourless [4][5][6].

Why tesamorelin gels: the underlying chemistry

Tesamorelin is a synthetic 44-amino-acid peptide, which is an analogue of growth hormone-releasing hormone (GHRH). Compared to short peptides, longer peptide chains generally have more surface area and more opportunities for hydrophobic (water-repelling) segments of the molecule to interact with each other, rather than remaining individually dissolved in water.

Following reconstitution, particularly at higher concentrations, these molecules can begin to bind together. This process is generally described in the pharmaceutical literature as aggregation, and increases the viscosity of the solution. In more pronounced cases, it produces visible clumping or a gel-like consistency [1][7].

This is described in peptide handling references as a physical phenomenon, not necessarily chemical degradation. The peptide molecules stick together rather than break down. It is worth noting, however, that in practice, once a solution visibly gels or turns cloudy, it is no longer considered suitable for use. The physical change also signals that the solution is no longer in the properly dissolved, homogeneous state required for accurate, safe dosing [1][4][5].

Several handling guides specifically flag tesamorelin, alongside a small number of other aggregation-prone peptides, as one of the products where this risk is elevated compared to more stable, shorter peptides [1][3][7].

What the official information actually says about prescribing

Tesamorelin is approved by the FDA under the brand names Egrifta (original formulation), Egrifta SV and Egrifta WR. It is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.

Since gelation and clouding is a recognised handling risk, the official prescribing information for each formulation is specific and consistent regarding the reconstitution technique [4][5][6]:

Use only the solvent supplied with the product. Sterile Water for Injections for Egrifta and Egrifta SV, or Water Bacteriostatic Water for Injection Egrifta WR. Do not use any alternative water source [4][5][6].

Not shake the vial. For Egrift and Egrift SV, the instructions are folding vials between hands for about 30 seconds. For Egrifta WR, instruction for use violining in a circle, that is rocking, so that mix powder and liquid [4][5][6].

Following reconstitution, the solution should be clear and colourless. The label clearly states: do not use if the solution is cloudy, discoloured or contains particulate matter [4][5][6].

Slight foaming upon reconstitution is not unusual. In itself, this does not necessarily indicate a problem [8].

Egrifta SV and the original Egrifta formulation are to be used immediately after reconstitution. Any unused reconstituted solution should be discarded, and should not be frozen or refrigerated [5][6]. Egrifta WR, another, more stable formulation, can be stored at room temperature both before and after reconstitution, and is designed for weekly, rather than daily, reconstitution [4].

Consistency across all three approved formulations, meaning never shake, always use the specified solvent, and always check clarity, reflects, how directly risk of gelling and clouding shaped the actual instructions handling of the product.

Most common actual causes of gelling

Drawing from FDA labelling combined with peptide handling and community troubleshooting sources, the factors most consistently linked to tesamorelin geling are these.

Shaking or vigorous vortexing instead of gentle mixing. Agitation increases the chances of the particles interacting and aggregating, rather than dissolving smoothly. This is precisely why every official label says „do not shake” [1][4][5][7].

Incorrect solvent or poor quality bacteriostatic/sterile water. Some community reports specifically describe switching to another brand or quality of bacteriostatic water as resolving persistent gelling issues. It is worth noting, however, that this is anecdotal rather than a controlled comparison [2].

Extreme temperatures or repeated temperature fluctuations, including the use of very hot or very cold water for reconstitution, or cycling the reconstituted vial between room temperature and the refrigerator [3][7].

High peptide concentration. Reconstitution with a smaller volume of solvent, yielding a more concentrated solution, increases the local concentration of peptide molecules and raises the probability of self-association and aggregation [1].

Improper or prolonged storage of the reconstituted solution. For products intended for immediate use (Egrifta, Egrifta SV), storage of the reconstituted solution, particularly in a freezer or through repeated fridge-room temperature cycling, is clearly contrary to the label instructions and is associated with clouding, thickening and clumping [3][5][6].

Contamination or degradation during preparation, which can also manifest as haze, although this is a distinct issue from simple gelation associated with aggregation [3].

How to reduce the risk of gelation

Allow the vial and solvent to reach a temperature closer to room temperature before reconstitution, rather than using them straight from the fridge or freezer [7].

Add the solvent slowly, directing it down the side of the vial rather than shooting it directly onto the lyophilised powder [1][7].

Stir gently. Roll the vial between your hands or swirl it in a slow circular motion, exactly as specified in the official instructions for Egrift and Egrift WR. Never shake it [4][5][6].

Leave the vial for a minute or two after initial mixing to allow for complete hydration before assuming that it has not dissolved. Uneven or incomplete hydration may appear as early cloudiness [7].

Avoid reconstitution at unnecessarily high concentrations; when performing the assay, do not use less solvent than intended if aggregation has been a recurring problem [1].

Use the solvent specified for your specific product or kit, and be careful about substituting a water source other than the one supplied or specified [4][5][6].

Once reconstituted, for formulations intended for immediate use, do not store the solution through repeated temperature changes. Use it promptly and discard any unused portion in accordance with label instructions [5][6].

What to do if your tesamorelin has already gelled

If you notice that a vial has become cloudy, thickened or has completely set into a gel:

Don’t use it. Every official source of information on prescribing is unequivocal in stating that the reconstituted solution must be clear, colourless and free from particulate matter in order to be used. Any solution that is cloudy, discoloured or contains particles should be discarded [4][5][6]. Community and handling sources reflect the same conclusion. As soon as it becomes visibly gel-like, the product is generally considered unsuitable for use, as you can no longer be certain of the actual concentration or condition of the peptide in the solution [2][3].

Don’t try to „fix” it” by heating, refreezing or vigorous shaking to break up the gel. None of these methods has been validated, and vigorous shaking is the opposite of what the official instructions recommend for handling this peptide in the first place [1][4].

If this has happened with an FDA-approved Egrifta, Egrifta SV or Egrifta WR product, please contact your prescribing doctor or pharmacist. There may be a product quality or handling issue that warrants reporting, and a replacement or further guidance may be appropriate.

If this has happened repeatedly in many vials from the same source, this pattern – as described in actual user reports – points either to a reconstitution or technical issue (the most easily rectifiable), or a problem with the quality of the product or the solvent, warranting a reconsideration of the source, rather than „just bad luck” every time [2][9].

Does gelation mean that the peptide has „gone bad” or is dangerous?

The available literature draws a distinction that is worth understanding. Aggregation and gelation are generally described as a physical change, involving the clumping together of molecules, and not necessarily the chemical breakdown of the peptide itself [1].

It is worth noting, however, that this distinction does not mean the gelled solution is okay to use. In practice, as soon as a peptide solution has visibly gelled or turned cloudy:

You can no longer be certain of the actual concentration of the active peptide that would be delivered in any given dose, as the material is no longer uniformly dissolved.

The official product labelling for an authorised pharmaceutical product treats visible turbidity and particulate matter as an automatic reason for rejecting the solution, regardless of the underlying mechanism [4][5][6].

There is no validated method for reliably confirming that a gelled solution has „regained” its original properties. Therefore, the conservative and label-compliant approach is to treat it as unusable and start with a fresh vial [2][4].

Why does my tesamorelin turn into a gel?

This is most often because the amino acid sequence of tesamorelin contains hydrophobic segments which make it more prone than many other peptides to molecular self-association (aggregation) upon dissolution, particularly at higher concentrations [1][7]. This inherent tendency is triggered or exacerbated by specific handling factors. Shaking rather than gentle mixing. The use of an incompatible or inferior-quality solvent. Extreme temperatures or fluctuations during reconstitution or storage. And reconstitution at a concentration that is too high for the volume of solvent used [1][2][3][7]. This is a genuine, documented characteristic of this particular peptide, rather than something unique to a single batch of the product, although poor technique or product quality may exacerbate it.

Does tesamorelin gel more than other peptides?

Yes. Many independent sources on the handling of peptides specifically highlight tesamorelin, alongside a small number of other peptides such as kisspeptin, as being more prone to gelation or clumping than typical shorter, less hydrophobic peptides [1]. This is due to its longer amino acid chain and the hydrophobic nature of parts of its sequence, which increases the tendency of dissolved molecules to interact with one another, rather than remaining individually solvated in water.

Is it normal for tesamorelin to gel, or does it mean something has gone wrong?

It is „normal” in the sense that it is a well-recognised risk specific to this peptide, not a bizarre occurrence. However, this does not mean it is expected or acceptable for a correctly reconstituted vial to end up gelled. A correctly reconstituted tesamorelin solution should be clear and colourless [4][5][6]. If it gels, something in the process—whether technique, diluent, temperature, concentration or storage—has pushed the peptide towards aggregation. It is worth identifying which factor, before reconstituting another vial in the same way.

Why does tesamorelin gel specifically when cooled?

Some users report that tesamorelin becomes more gel-like after being chilled or following repeated transfers between room temperature and the fridge [3][7]. Temperature changes affect the hydration and aggregation behaviour of protein-like molecules. The FDA labelling for Egrift and Egrift SV specifically instructs that the reconstituted solution should be used immediately and should not be frozen or refrigerated at all. It is intended as a single-use product for immediate administration, not for storage [5][6].

Egrifta WR is a different, more temperature-stable formulation designed to be stored at room temperature both before and after reconstitution. This is a useful illustration of how the risk of gelation can depend heavily on the specific formulation and excipients, not just the peptide itself [4][3].

Why does tesamorelin gel even without refrigeration, at room temperature?

Temperature is not the only variable. Concentration, mixing technique and solvent quality all play independent roles [1][2][7]. One source specifically notes that tesamorelin may thicken or gel at room temperature just as it does in the fridge. Temperature does not eliminate the underlying risk of aggregation. It simply shifts which failure mode is more likely to predominate [3]. Therefore, official instructions place strong emphasis on gentle mixing techniques and the use of the correct solvent, not merely on temperature control alone.

What should I do if my tesamorelin has gelled after reconstitution?

Discard it and do not inject it. The official prescribing information for each FDA-approved tesamorelin formulation states that the reconstituted solution must be clear and colourless, free from particulates or discolouration, in order to be used [4][5][6]. A gelled or cloudy solution does not meet this standard, and there is no reliable way to „fix” or reverse the gelling to restore confidence in the concentration or safety of the solution. If this is a recurring problem, review your reconstitution technique (gently rolling or rocking, never shaking), ensure you are using the correct, high-quality solvent, and avoid extreme temperatures or fluctuations during preparation and storage [1][2][4][7].

How can I prevent tesamorelin from gelating next time?

Reconstitute gently. Roll or swirl the vial rather than shaking it, exactly as instructed by the official Egrifta labelling [4][5][6]. Allow the vial and diluent to approach room temperature before mixing, rather than using them straight from the fridge or freezer. Add the diluent slowly down the side of the vial rather than directly onto the powder. Avoid reconstitution at an unnecessarily high concentration [1][7]. Use the specific diluent supplied with or specified for your product, as some community reports link the quality and type of diluent to gelation issues [2]. If using a formulation intended for immediate use, do not store the reconstituted solution through repeated temperature changes. Use it and discard what remains, in accordance with the label instructions [5][6].

Does the gelation of tesamorelin mean that the peptide has degraded or lost its potency?

It is described in the literature mainly as a phenomenon of physical aggregation, not necessarily the chemical degradation of the peptide itself [1]. This technical distinction does not, however, make a gelled solution usable. As soon as it has visibly gelled or gone cloudy, you cannot be certain of the actual concentration delivered by any given dose. Official product labelling treats visible turbidity or particulate matter as an automatic reason to discard the solution, regardless of the precise underlying mechanism [4][5][6]. Treat a gelled vial as compromised and unusable, rather than trying to determine whether potency specifically has been affected.

Is gelled tesamorelin dangerous to inject?

The primary concern is not necessarily acute toxicity. It is that you lose the ability to confirm the concentration and actual state the peptide is in. Injecting particulates or an improperly dissolved, heterogeneous solution carries general injection safety concerns of its own, such as inconsistent dosing and the potential for reduced sterility if the gelation process involved contamination. Official labelling is clear that a solution showing particulates, cloudiness or discoloration should not be used [4][5][6]. This instruction should be followed, rather than assuming that a gelled vial is „probably still fine”.

Why have some of my vials gelled while others from the same batch haven't?

This pattern, reported by some users experiencing gelation in multiple vials from a single purchase, often indicates a consistent factor either in the technique or in the product or solvent itself, rather than random chance [2][9]. If every vial reconstituted in the same way with the same solvent gels, it is a strong signal to change the solvent, adjust the technique (slower mixing, no shaking, more moderate temperature), or reconsider the source of the product, rather than assuming each incident is unrelated.

Is there a difference in gelation risk between FDA-approved Egrifta products and other sources of tesamorelin?

The underlying peptide chemistry, and thus the underlying propensity to aggregate, is the same molecule regardless of the source [3]. However, FDA-approved formulations (Egrifta, Egrifta SV, Egrifta WR) have undergone formal pharmaceutical formulation development, with specific solvents, excipients and reconstitution protocols designed and validated for that exact product. Their prescribing information provides precise, tested instructions [4][5][6].

Non-pharmaceutical, research-labelled tesamorelin products do not carry the same level of formulation validation. Solvent quality, excipients and manufacturing consistency can vary significantly between suppliers, which several sources link to differences in the actual rate of gelation [1][2][9].

Disclaimer

This content is for educational and informational purposes only and should not be construed as medical advice, a diagnosis, or a therapeutic recommendation. Tesamorelin (Egrifta, Egrifta SV, Egrifta WR) is a US Food and Drug Administration (FDA) approved, prescription-only medicine indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The information presented in this article regarding reconstitution and handling reflects the manufacturer's official prescribing information and publicly available sources regarding peptide handling at the time of writing and does not replace the official leaflet enclosed with a specific product or the guidance of a doctor or pharmacist. Tesamorelin products sold outside pharmaceutical channels as „research compounds” are not FDA approved and are not subject to the same formulation validation, quality, or manufacturing controls. This article does not constitute medical advice or self-administration instructions, and nothing in it should be construed as an encouragement to use unapproved peptide products.